KR100567608B1 - 메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도 - Google Patents
메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도 Download PDFInfo
- Publication number
- KR100567608B1 KR100567608B1 KR1020007008836A KR20007008836A KR100567608B1 KR 100567608 B1 KR100567608 B1 KR 100567608B1 KR 1020007008836 A KR1020007008836 A KR 1020007008836A KR 20007008836 A KR20007008836 A KR 20007008836A KR 100567608 B1 KR100567608 B1 KR 100567608B1
- Authority
- KR
- South Korea
- Prior art keywords
- metformin
- fibrate
- composition
- combination
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
Description
처 치 | 혈 당 (g/ℓ) | 콜레스테롤 (g/ℓ) | 트리글리세리드 (g/ℓ) |
절대 대조군 | 1.06 ±0.06 | 0.50 ±0.02 | 0.86 ±0.04 |
스트렙토조토신 단독 | 2.68 ±0.06°° | 0.65 ±0.04°° | 1.25 ±0.07°° |
메트포르민(50 mg/kg) | 1.74 ±0.14** | 0.61 ±0.03 | 0.85 ±0.10** |
클로피브레이트(100 mg/kg) 페노피브레이트(50 mg/kg) 벤자피브레이트(50 mg/kg) | 2.58 ±0.11 1.92 ±0.20** 2.20 ±0.21* | 0.63 ±0.03 0.45 ±0.02** 0.52 ±0.05** | 0.93 ±0.11* 0.61 ±0.10** 0.81 ±0.11** |
클로피브레이트(100 mg/kg) + 메트포르민(50 mg/kg) 페노피브레이트(50 mg/kg) + 메트포르민(50 mg/kg) 벤자피브레이트(50 mg/kg) + 메트포르민(50 mg/kg) | 1.72 ±0.09** 1.44 ±0.11** 1.43 ±0.05**§ | 0.63 ±0.02 0.56 ±0.05 0.48 ±0.04**§ | 0.94 ±0.08** 0.63 ±0.12** 0.62 ±0.02**§ |
°p > 0.01 절대 대조군과 MIDD STZ 쥐간의 비교 * p > 0.05, ** p > 0.01 대조군과 치료 STZ 간의 비교 §p > 0.05 메트포르민 단독과 조합물 간의 비교 |
Claims (12)
- 활성 성분으로서, (i) 메트포르민(metformin) 또는 그의 약학적으로 허용가능한 염 및 (ii) 페노피브레이트(fenofibrate) 및 벤자피브레이트(benza-fibrate)로부터 선택된 피브레이트를, 하나 이상의 약학적으로 허용가능한 부형제와 조합으로 함유하는 비(非)인슐린 의존성 당뇨병의 과혈당증 저하용 조성물.
- 삭제
- 제 1 항에 있어서, 비(非)지방이상성 환자의 비인슐린 의존성 당뇨병의 과혈당증 저하용 조성물.
- 제 1 항에 있어서, 메트포르민 또는 이의 약학적으로 허용가능한 염 대 피브레이트의 중량비가 1 : 1 내지 5 : 1 인 조성물.
- 제 1 항에 있어서, 메트포르민염이 염화수소, 푸마레이트, 엠보네이트(embonate) 또는 클로로페녹시아세테이트인 조성물.
- 제 1 항에 있어서, 경구 투여에 적합한 조성물.
- 삭제
- 삭제
- 삭제
- 제 1 항에 있어서, 약제 조합물이 메트포르민, 또는 이의 약학적으로 허용가능한 염, 그리고 피브레이트를 함유하는 단위 용량의 형태인 조성물.
- 제 10 항에 있어서, 단위 용량이 메트포르민 100 내지 1000 mg 및 페노피브레이트 50 내지 300 mg 을 함유하는 조성물.
- 제 10 항에 있어서, 단위 용량이 메트포르민 100 내지 1000 mg 및 벤자피브린 50 내지 600 mg 을 함유하는 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9801709A FR2774591B1 (fr) | 1998-02-12 | 1998-02-12 | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
FR98/01709 | 1998-02-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010040925A KR20010040925A (ko) | 2001-05-15 |
KR100567608B1 true KR100567608B1 (ko) | 2006-04-04 |
Family
ID=9522912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007008836A KR100567608B1 (ko) | 1998-02-12 | 1999-01-30 | 메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도 |
Country Status (28)
Country | Link |
---|---|
US (1) | US6372790B1 (ko) |
EP (1) | EP1054665B1 (ko) |
JP (1) | JP4767411B2 (ko) |
KR (1) | KR100567608B1 (ko) |
CN (1) | CN1151785C (ko) |
AR (1) | AR018286A1 (ko) |
AT (1) | ATE204754T1 (ko) |
AU (1) | AU746821B2 (ko) |
BR (1) | BRPI9907866B8 (ko) |
CA (1) | CA2320039C (ko) |
CZ (1) | CZ290101B6 (ko) |
DE (1) | DE69900249T2 (ko) |
DK (1) | DK1054665T3 (ko) |
ES (1) | ES2162517T3 (ko) |
FR (1) | FR2774591B1 (ko) |
HK (1) | HK1034913A1 (ko) |
HU (1) | HU224619B1 (ko) |
ID (1) | ID26254A (ko) |
MY (1) | MY118164A (ko) |
NO (1) | NO328314B1 (ko) |
PL (1) | PL196874B1 (ko) |
PT (1) | PT1054665E (ko) |
RU (1) | RU2207850C2 (ko) |
SK (1) | SK283212B6 (ko) |
TW (1) | TW518222B (ko) |
UA (1) | UA70315C2 (ko) |
WO (1) | WO1999040904A2 (ko) |
ZA (1) | ZA991077B (ko) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4278863B2 (ja) * | 1997-12-08 | 2009-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | メトホルミンの新規塩および方法 |
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
FR2796551B1 (fr) * | 1999-07-23 | 2003-07-25 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
FR2796940B1 (fr) * | 1999-07-26 | 2005-04-08 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
EP1246792B1 (en) * | 2000-01-13 | 2014-08-13 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6531158B1 (en) * | 2000-08-09 | 2003-03-11 | Impax Laboratories, Inc. | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients |
JP4829411B2 (ja) * | 2001-02-23 | 2011-12-07 | キッセイ薬品工業株式会社 | C型慢性肝炎治療剤 |
GB0119480D0 (en) | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
ATE411010T1 (de) | 2002-12-13 | 2008-10-15 | Jagotec Ag | Topische nanopartikel-spironolacton-formulierung |
FR2851734B1 (fr) * | 2003-02-28 | 2006-06-09 | Galenix Innovations | Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede |
FR2858556B1 (fr) * | 2003-08-06 | 2006-03-10 | Galenix Innovations | Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation |
US8062664B2 (en) * | 2003-11-12 | 2011-11-22 | Abbott Laboratories | Process for preparing formulations of lipid-regulating drugs |
CN101897970A (zh) | 2003-12-19 | 2010-12-01 | 奥加生物药业(I.P.3)有限公司 | 用于治疗糖尿病的组合物和方法 |
EP1559419A1 (en) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
JP4901218B2 (ja) * | 2004-02-09 | 2012-03-21 | あすか製薬株式会社 | 併用医薬 |
EP1591114A1 (en) * | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
US20060286182A1 (en) * | 2005-06-21 | 2006-12-21 | Abeille Pharmaceuticals, Inc. | Synergistic cinnamon combinations and methods for enhancing insulin activity |
GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
US20090318496A1 (en) | 2006-08-04 | 2009-12-24 | Aska Pharmaceutical Co., Ltd. | Preparation containing fibrate agent and process for producing the same |
CN101342164B (zh) * | 2007-08-21 | 2011-04-20 | 阜新市仙鹤制药有限责任公司 | 苯扎贝特控释制剂及其制备方法 |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
ES2344183B1 (es) * | 2009-02-18 | 2011-06-10 | Italfarmaco, S.A. | Uso de agentes sensibilizantes a insulina por via vaginal. |
US9339458B2 (en) * | 2009-02-18 | 2016-05-17 | Itf Research Pharma, S.L.U. | Use of vaginal insulin sensitizing agents |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ppar活性化剤 |
US9382187B2 (en) * | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
CN104684889A (zh) * | 2012-07-10 | 2015-06-03 | 西蒂斯制药有限责任公司 | 二甲双胍的三盐形式 |
US8765811B2 (en) * | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9505709B2 (en) | 2014-05-05 | 2016-11-29 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
US10166246B2 (en) | 2014-05-27 | 2019-01-01 | City Of Hope | TGR5 agonist complexes for treating diabetes and cancer |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
MX2016016830A (es) | 2014-06-18 | 2017-07-07 | Thetis Pharmaceuticals Llc | Complejos de aminoacidos minerales de agentes activos. |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
FR3050112B1 (fr) * | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
KR102437682B1 (ko) | 2016-06-03 | 2022-08-29 | 테티스 파마수티컬스 엘엘씨 | 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법 |
WO2018058109A1 (en) * | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
FR3056908B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
GB2599950A (en) * | 2020-10-16 | 2022-04-20 | Zentiva Ks | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same |
WO2023119100A1 (en) * | 2021-12-22 | 2023-06-29 | Mankind Pharma Ltd. | Stable pharmaceutical compositions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2264525B1 (ko) * | 1974-03-22 | 1977-11-04 | Expl Marques Brevets Et | |
US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
DE3729209A1 (de) * | 1987-09-01 | 1989-03-09 | Boehringer Mannheim Gmbh | Verwendung von bezafibrat zur behandlung von diabetes |
JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
WO1998005331A2 (en) * | 1996-08-02 | 1998-02-12 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
-
1998
- 1998-02-12 FR FR9801709A patent/FR2774591B1/fr not_active Expired - Lifetime
-
1999
- 1999-01-30 DE DE69900249T patent/DE69900249T2/de not_active Expired - Lifetime
- 1999-01-30 DK DK99910169T patent/DK1054665T3/da active
- 1999-01-30 CZ CZ20002828A patent/CZ290101B6/cs not_active IP Right Cessation
- 1999-01-30 RU RU2000123567/14A patent/RU2207850C2/ru active
- 1999-01-30 CA CA002320039A patent/CA2320039C/en not_active Expired - Lifetime
- 1999-01-30 SK SK1156-2000A patent/SK283212B6/sk not_active IP Right Cessation
- 1999-01-30 EP EP99910169A patent/EP1054665B1/en not_active Expired - Lifetime
- 1999-01-30 ES ES99910169T patent/ES2162517T3/es not_active Expired - Lifetime
- 1999-01-30 CN CNB998029041A patent/CN1151785C/zh not_active Expired - Lifetime
- 1999-01-30 JP JP2000531156A patent/JP4767411B2/ja not_active Expired - Lifetime
- 1999-01-30 ID IDW20001765A patent/ID26254A/id unknown
- 1999-01-30 HU HU0100801A patent/HU224619B1/hu active IP Right Grant
- 1999-01-30 WO PCT/EP1999/000614 patent/WO1999040904A2/en active IP Right Grant
- 1999-01-30 US US09/601,618 patent/US6372790B1/en not_active Expired - Lifetime
- 1999-01-30 KR KR1020007008836A patent/KR100567608B1/ko not_active IP Right Cessation
- 1999-01-30 PL PL342665A patent/PL196874B1/pl unknown
- 1999-01-30 UA UA2000095172A patent/UA70315C2/uk unknown
- 1999-01-30 BR BR9907866A patent/BRPI9907866B8/pt not_active IP Right Cessation
- 1999-01-30 AT AT99910169T patent/ATE204754T1/de active
- 1999-01-30 PT PT81108560T patent/PT1054665E/pt unknown
- 1999-01-30 AU AU29233/99A patent/AU746821B2/en not_active Expired
- 1999-02-09 MY MYPI99000445A patent/MY118164A/en unknown
- 1999-02-10 TW TW088102063A patent/TW518222B/zh not_active IP Right Cessation
- 1999-02-10 ZA ZA9901077A patent/ZA991077B/xx unknown
- 1999-02-12 AR ARP990100598A patent/AR018286A1/es active IP Right Grant
-
2000
- 2000-08-11 NO NO20004056A patent/NO328314B1/no not_active IP Right Cessation
-
2001
- 2001-08-15 HK HK01105732A patent/HK1034913A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100567608B1 (ko) | 메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도 | |
US20080300293A1 (en) | Combination of an dpp-iv inhibitor and a ppar-alpha compound | |
JPH05262651A (ja) | 向精神薬の安定化溶液 | |
KR20060100440A (ko) | 각결막 장해 치료제 | |
EP0633777B1 (en) | Parenteral solutions containing 3-dialkylaminoethoxybenzoyl-benzofurans | |
DE69910600T2 (de) | Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist | |
KR20090024248A (ko) | Cxcr2의 선택적 길항제 또는 cxcr1과 cxcr2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법 | |
KR20040058266A (ko) | 메트포르민 및 4-옥소부탄산의 조합물을 포함하여이루어지는 약제학적 조성물 및 당뇨병을 치료하기 위한이의 용도 | |
Frishman et al. | Ultra-short-acting β-adrenergic blockers | |
EP1244454B1 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen | |
US20040014797A1 (en) | Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative | |
US4219566A (en) | Phenylglyoxylic acids and derivatives thereof | |
MXPA06008180A (es) | Metodo para tratar disfuncion erectil. | |
US4239779A (en) | Use of phenylglyoxylic acids and derivatives thereof in the treatment of ischemic heart disease | |
MXPA00007739A (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia | |
KR20210046115A (ko) | 니아신 유도체 및 이를 함유하는 약학 조성물 | |
EP0488041A2 (en) | A pharmaceutical composition for cytomegalovirus infection | |
JPH01283224A (ja) | 抗高血圧の組み合わせ調合物 | |
JPH02286617A (ja) | 血管新生阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130228 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140303 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150302 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160304 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170302 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180316 Year of fee payment: 13 |
|
EXPY | Expiration of term |